SCHEMBL5762299

SCHEMBL5762299

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(S(=O)(=O)NCC4CCCCC4)cc3)ccc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.46
CNR2 P34972 8/20 0.44
CNR1 P21554 5/20 0.44
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
STAT3 P40763 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
IDH2 P48735 1/20 0.37
NPY1R P25929 1/20 0.37
NPY5R Q15761 1/20 0.37
GBA1 P04062 1/20 0.37
AR P10275 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5860196 0.87 ALDH1A1 (0.44) MAPK1SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL5762163 0.87 SCN9A (0.38) HDAC4CNR2CNR1KMT2AMAPK1
SCHEMBL5860258 0.86 SMN1; SMN2 (0.44) MAPK1SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL5761054 0.83 CA1 (0.46) SMN1; SMN2ALDH1A1USP2LMNAMAPT
SCHEMBL5860408 0.83 GAA (0.46) HDAC4KMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL5762259 0.82 ALDH1A1 (0.49) CNR2KMT2ASMN1; SMN2ALDH1A1MEN1
SCHEMBL5757048 0.82 MAPT (0.46) KMT2ASMN1; SMN2ALDH1A1MEN1LMNA
SCHEMBL5762244 0.80 CYP1A2 (0.41) KMT2ASMN1; SMN2ALDH1A1MEN1LMNA
SCHEMBL5759747 0.80 KMT2A (0.37) KMT2AALDH1A1MEN1LMNAAR
SCHEMBL5762538 0.80 AR (0.51) SMN1; SMN2ALDH1A1USP2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT HDAC4 674/4885CNR2 105/4885CNR1 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.